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Nosocomial candidiasis is a major concern in tertiary care hospitals worldwide. This infection generally
occurs in patients with degenerative and neoplastic diseases and is considered the fourth most frequent cause
of bloodstream infections. Diagnosis of candidemia or hematogenous candidiasis has been problematic be-
cause clinical signs and symptoms are nonspecific, leading to delays in diagnosis and, consequently, delays in
appropriate antifungal therapy. We developed an inhibition enzyme-linked immunosorbent assay (ELISA) for
detection of a 65-kDa antigen in an experimental model of candidemia and for diagnosis of patients in intensive
care units (ICUs) with suspected candidemia. An anti-65-kDa monoclonal antibody was tested for detection of
the 65-kDa antigen produced by Candida albicans, Candida tropicalis, and Candida parapsilosis in murine
candidemia models. The 65-kDa antigen was detected in sera at concentrations ranging from 0.012 to 3.25
g/ml. A total of 20 human patients with candidemia were then evaluated with the inhibition ELISA using
sequential sera. Sixteen (80%) patients had the 65-kDa antigen in concentrations ranging from 0.07 to 5.0
g/ml. Sequential sera from patients with candidemia presented three different patterns of antigenemia of the
65-kDa molecule: (i) total clearance of antigenemia, (ii) initial clearance and relapse of antigenemia, and (iii)
partial clearance of antigenemia. Our results indicate detection of the 65-kDa protein may be a valuable tool
for the diagnosis of candidemia by C. albicans, C. tropicalis, and C. parapsilosis.
Nosocomial candidiasis is a major concern in tertiary care
hospitals worldwide. This infection generally occurs in patients
with degenerative and neoplastic diseases exposed to broad-
spectrum antibiotics, immunosuppressive drugs, and invasive
medical procedures (10, 11, 32, 40, 48). The incidence of in-
vasive candidiasis has increased over the past two decades, and
candidemia is now considered the fourth most frequent cause
of bloodstream infections (50, 53). A recent nationwide sur-
veillance study, conducted in public general tertiary care hos-
pitals in Brazil, found an incidence of 2.69 episodes/1,000 ad-
missions, a rate 2 to 8 times higher than that observed in
medical centers from Northern Hemisphere countries (10). In
South America, most candidemic episodes are related to Can-
dida albicans, Candida tropicalis, and Candida parapsilosis
strains; Candida glabrata has been scarcely reported (9–12, 15,
21, 25, 42, 55). This is in contrast to United States and Euro-
pean medical centers, where C. glabrata is considered a major
pathogen.
Diagnosis of candidemia or hematogenous candidiasis has
been problematic. The clinical signs and symptoms are non-
specific; therefore, the diagnosis and, consequently, appropri-
ate antifungal therapy are delayed. Even in patients with au-
topsy-proven systemic candidiasis, positive diagnoses from
blood cultures ranged from 40 to 60% (51–53).
Antigen detection for the serodiagnosis of invasive Candida
infections has been reported (5, 6, 13, 14, 18–20). Matthews
and Burnie developed an immunobinding method for detec-
tion of a 47-kDa cytoplasmatic protein antigen in patients with
systemic candidiasis (34). An immunoassay detecting a 48-kDa
antigen of Candida, subsequently recognized as enolase (13,
33), is available for the diagnosis of invasive candidiasis (54).
Latex agglutination tests are based on the detection of man-
nan, a cell wall component that is the most widely studied
antigen in patients with candidiasis (5, 20). Commercial tests
(Pastorex Candida assay and Cand-Tec assay) have been used
to detect this molecule in sera. Colorimetric assays (Fungitec
G and Fungitec G MT) detect -D-glucan, a major structural
component of the fungal cell wall, in serum and have been used
for diagnosis of fungal infections. Studies show the concentra-
tion of -D-glucan is increased in experimental models of fun-
gal infections (35–38), as well as in the plasma of patients with
mycosis (20, 36).
Various tests have been developed based on detection of
antibodies, antigens, and metabolites, although, they are all
time-consuming and lack either specificity or sensitivity (50). In
C. albicans, a 65-kDa mannoprotein (Mp65) is a structural and
secreted component of the fungus. This mannoprotein is par-
ticularly observed in extracellular fractions of hyphal cells (1, 8,
17, 44–46). Mp65 is also present in both the structural and
secretory mannoprotein material and is recognized by periph-
eral blood T cells of practically all healthy individuals (quasi-
universal antigen) (1, 44, 45), making it a potential target for
immunodiagnosis of patients with suspected candidemia.
Arancia et al. (1) used real-time PCR to detect and quantify C.
albicans in sera from patients with invasive candidiasis. This
assay was specific for a DNA fragment containing the gene for
the 65-kDa mannoprotein of C. albicans (CaMP65). The assay
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was shown to be sensitive and specific for C. albicans, allowing
quantitative detection of this fungus in clinical samples.
The inhibition enzyme-linked immunosorbent assay (inh-
ELISA) is an enzyme immunoassay (EIA) to detect circulating
antigens in sera of patients with invasive fungal infections. This
test uses a species-specific murine monoclonal antibody (MAb)
with high sensitivity and specificity and is useful in diagnosis
and follow-up of paracoccidioidomycosis patients. It is also
useful for antigen detection in the cerebrospinal (28) and bron-
choalveolar (27, 29–31) fluids of these patients.
In this study, our intention was to demonstrate that inh-
ELISA is a sensitive detection method able to detect nano-
grams of antigen in serum samples from patients with candi-
demia and not to compare it or show its superiority to other
assays. Na and Song previously compared three serological
methods of detecting C. albicans secreted aspartyl proteinase
antigen (39); they found inh-ELISA had 93.9% sensitivity and
96.0% specificity and detected concentrations ranging from 6.3
to 19.0 ng/ml. The sensitivity and specificity for standard
ELISA were 69.7 and 76.0%, respectively; while for capture
ELISA, the sensitivity and specificity were 93.9 and 92.0%,
respectively. The results of Na and Song showed inh-ELISA
with MAb CAP1 effectively detected circulating secreted as-
partyl proteinase antigen and suggest it may be useful for the
diagnosis and treatment monitoring of invasive candidiasis.
The aim of this study was to standardize an alternative inh-
ELISA for detection of a 65-kDa antigen, present in C. albi-
cans, C. tropicalis, and C. parapsilosis, using a MAb specific for
the 65-kDa Candida protein. The assay could be used for
diagnosis and follow-up of patients with candidemia. The
present study involved five different stages: (i) identification of
an immunodominant 65-kDa antigen of C. albicans that is
common to C. tropicalis and C. parapsilosis, (ii) production
of an anti-C. albicans 65-kDa-molecule MAb for detection
of the immunodominant antigen mentioned above, (iii) ap-
plication of the MAb to the inh-ELISA, (iv) characteriza-
tion of antigenemia in an animal model, and (v) evaluation
of the developed inh-ELISA with sera from patients with
candidemia.
MATERIALS AND METHODS
Fungal isolates. Isolates of C. albicans (ATCC 90028), Candida parapsilosis
(ATCC 22019), Candida tropicalis (ATCC 750), and Candida glabrata (ATCC
90030) were obtained from the yeast stock collection of the Special Mycology
Laboratory, Federal University of Sa˜o Paulo.
Candida exoantigens. Each Candida species was grown on Sabouraud agar
(three tubes) for 3 days at 36°C. All growth was transferred to a 250-ml Erlen-
meyer flask containing 50 ml modified Lee’s medium without amino acids
(MLMwAA) (23) under agitation (50 rpm). MLMwAA, as modified by Tronchin
et al. (49), contains 5.0 g/liter (NH4)2SO4, 0.2 g/liter MgSO4  7H2O, 2.5 g/liter
K2HPO4, 5.0 g/liter NaCl, 10.0 g/liter glucose, and 0.04 g/liter biotin at pH 6.8.
This constituted a preinoculum, which was then transferred to a 1-liter Erlen-
meyer flask containing the above medium for 7 days at 36°C under agitation (50
rpm). Then, the growth was killed with merthiolate (0.2 g/liter) and filtered. The
filtrate was concentrated under vacuum at 45°C to a volume of 30 ml and
dialyzed against distilled water for 48 h. Protein content was determined by the
method of Bradford (4).
Exoantigens of heterologous fungi. Exoantigens of Histoplasma capsulatum,
Aspergillus fumigatus, and Paracoccidioides brasiliensis were prepared according
to Smith and Goodman (43), Biguet et al. (3), and Camargo et al. (7), respec-
tively. Sporothrix schenckii and Trichosporum rubrum exoantigens were obtained
according to the protocol described by Camargo et al. for Paracoccidioides
brasiliensis (7). Protein content was determined by the method of Bradford (4).
SDS-PAGE and Western blot for determination of immunodominant anti-
gens. The exoantigens obtained from the C. albicans, C. tropicalis, and C. parap-
silosis cultures underwent sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (22) and Western blotting as previously described (47).
Briefly, after transferring proteins to nitrocellulose membrane, the membrane
was blocked with Tris-buffered saline (20 mM Tris-HCl, 150 mM NaCl, pH 7.2)
containing 5% nonfat dry milk for 2 h at room temperature. The membranes
were then incubated with previously obtained rabbit anti-C. albicans hyperim-
mune sera (1:50 dilution) for 1 h at room temperature. Next, the membranes
were washed three times with phosphate-buffered saline (PBS)–Tween 20 and
incubated with a 1:1000 dilution of peroxidase-conjugated anti-rabbit immuno-
globulin G (IgG) (Sigma-Aldrich) for 1 h at 37°C. The reaction was developed in
a solution containing 5 mg of 3,3-diaminobenzidine (DAB; Sigma) and 10 l of
H2O2 in 50 ml of Tris buffer, pH 7.4. The membranes were washed, dried,
analyzed, and stored for documentation.
Electroelution of C. albicans 65-kDa protein. Various SDS-PAGE gels of C.
albicans exoantigens were run and stained with 0.3 M copper chloride (CuCl2).
The region containing the 65-kDa molecule was excised from gels and electro-
eluted in an electroelution chamber (Isco model 1750 electrophoretic concen-
trator; Isco, Inc., Lincoln, NE). Electroelution was performed for 3 to 5 h in 192
mM glycine and 25 mM Tris-HCl, pH 8.3, at a 2-A constant current. Proteins
were eluted and dialyzed exhaustively against distilled water. The concentration
was determined by the method of Bradford (4).
MAb production of the anti-65 kDa C. albicans molecule. The MAb was
produced by the method of Lopes and Alves (26). Of note, the production of
MAb was only initiated after a pilot study showed the antigen was recognized by
polyclonal antibody. Six-week-old BALB/c mice were immunized every week for
3 weeks subcutaneously with 50 g of C. albicans 65-kDa protein in PBS incor-
porated into Freund’s complete adjuvant for the first injection and in incomplete
Freund’s adjuvant for the subsequent ones. Injections were always made at four
different sites in the axillary and inguinal regions at final volumes of 100 l per
site. Before each immunization, mice were bled through the ocular plexus and
the serum was separated by centrifugation and stored at 20°C. Final immuni-
zations (50 g of 65-kDa protein in 100 l of PBS intravenously) were performed
2 days before cell fusion, according to the method of Lopes and Alves (26).
Positive colonies were screened by an EIA, as described below. After cloning by
limiting dilution and expanding positive clones, large amounts of antibodies were
obtained by producing ascites in BALB/c mice previously primed with Pristane
(Sigma). MAbs were purified from culture supernatants and ascites by affinity
chromatography on a protein A column. Ig isotyping was performed with the
Clone Selector mouse MAb screening kit (Bio-Rad) according to the manufac-
turer’s instructions. Animal experiments were approved by the Institutional
Animal Care and Use Committee of the Federal University of Sa˜o Paulo.
Antibody screening by EIA. The EIA was performed as described by Puccia
and Travassos (41). Briefly, polyvinyl microplates (Corning Costar) were coated
with 50 l of a 2-g/ml solution of purified 65-kDa protein in PBS for 1 h at room
temperature. After blocking free sites with PBS containing 5% nonfat milk for
2 h at room temperature, 50 l of culture supernatant or purified MAb was
added to each well. After 1 h of incubation at 37°C, wells were thoroughly washed
with PBS containing 0.5% gelatin (Difco) and 0.05% Tween 20 (Sigma) (PBS-
T-G) and treated with affinity-purified peroxidase-conjugated goat anti-mouse Ig
(Bio-Rad) for 1 h at 37°C. This was followed by three washes with PBS-T-G.
Reactions were developed by the addition of o-phenylenediamine in 0.1 M
acetate-phosphate buffer, pH 5.8, stopped with 4 N sulfuric acid, and read in a
Titertek Multiskan EIA reader at 492 nm.
Specificity of MAb against 65-kDa protein. The exoantigens from C albicans,
C. tropicalis, C. parapsilosis, H. capsulatum, A. fumigatus, P. brasiliensis, S.
schenckii, and T. rubrum were subjected to SDS-PAGE (22) and Western blot-
ting (47). Briefly, the membrane was blocked with Tris-buffered saline (20 mM
Tris-HCl, 150 mM NaCl, pH 7.2) containing 5% nonfat dry milk for 2 h at room
temperature. The membrane was then incubated with anti-65 kDa MAb (10
g/ml) for 1 h at room temperature. Then, the membrane was washed three
times with PBS-Tween 20 and incubated with a 1:1,000 dilution of peroxidase-
conjugated anti-mouse IgG (Sigma) for 1 h at 37°C. The reaction was developed
in a solution containing 5 mg of DAB (Sigma) plus 10 l of H2O2 in 50 ml of Tris
buffer, pH 7.4. The membrane was washed, dried, and stored for documentation.
inh-ELISA for 65-kDa molecule detection. For detection of the 65-kDa mol-
ecule by inh-ELISA, we followed a method described by Go´mez et al. (16) and
Marques-da-Silva et al. (33), based on the method described by Le Pape and
Deunff (24). An inh-ELISA was developed for serum samples. The diluting
buffer used in the serum experiments consisted of a pool of normal human serum
(NHS; 1:10 dilution) in 0.05% PBS–Tween 20 (PBS-Tween) and 20 mM MgCl2.
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Purified anti-65 kDa MAb was used (10 mg/ml), and all samples were diluted 1:2
in diluting buffer. The method is illustrated in detail in Fig. 1.
Pretreatment of immune sera for use in inh-ELISA. Aliquots of immune
serum (200 l) were mixed with an equal volume of 0.1 M EDTA (Sigma), pH
7.2, and boiled at 100°C for 3 to 5 min. The tubes were cooled and centrifuged
at 13,000  g for 30 min. The supernatant was used for the test.
Inhibition plates. An inhibition standard curve was constructed by adding
different concentrations of C. albicans 65-kDa protein (from 1 ng/ml to 30 g/ml)
to 100 l of pooled NHS and then adding 100 l of the standardized concen-
tration of anti-65 kDa protein MAb. NHS (diluted 1:2 in diluting buffer) was
used as a negative control. All standards, samples, and controls were tested in
triplicate. Samples were plated onto 96-well flat microtiter plates (Corning
Costar), previously blocked with 200 l of 5% nonfat milk per well, made up in
PBS-Tween, for 2 h at 37°C. Plates were mixed in a shaker for 30 min at room
temperature and then incubated overnight at 4°C.
Reaction plates. Maxisorp polystyrene plates (Corning Costar) were coated
with 500 ng of Candida albicans 65-kDa protein in 0.06 M carbonate buffer, pH
9.6 (100 l/well). The plates were left at room temperature for 30 min and then
incubated overnight at 4°C. After incubation, the plates were washed three times
with PBS-Tween and blocked with 200 l per well of 1% bovine serum albumin
in PBS for 1 h at 37°C. After three more washes, 100 l from each inhibition
plate well (containing a mixture of the MAb circulating complexes and free
MAb) was transferred to the respective wells in the reaction plate and incubated
for 2 h at 37°C. After being washed as described above, 100 l of goat anti-mouse
IgG-peroxidase (Sigma) was added, and the plates were incubated for 1 h at
37°C. After further washings, the reaction was developed with SuperSignal West
Pico Chemiluminescent solution (1:10) (Pierce biotechnology). Optical densities
(ODs) were measured at 470 nm with a Chemiluminescent ELISA reader (Spec-
traMax). The OD at 470 nm was then plotted on a standard curve constructed
from the data derived from MAb titration with NHS containing known quantities
of 65-kDa protein, as described above. The degree of inhibition of MAb binding
was shown to be reciprocal to the concentration of circulating antigen in the
sample. The cutoff point was established as the receiver operator characteristic
curve.
Neutropenic model of disseminated Candida infection for detection of 65-kDa
protein. For determination of circulating antigens in an experimental model of
candidemia, 6-week-old, 22- to 24-g BALB/c female mice (n 21) were rendered
neutropenic (absolute neutrophil count of 100/ml) by administration of 150
mg/kg of intraperitoneal (i.p.) cyclophosphamide 4 days prior to infection. This
was followed by a second dose of 100 mg/kg i.p. cyclophosphamide 1 day prior to
infection and then 100 mg/kg i.p. cyclophosphamide every other day thereafter.
Twenty-four hours after the second dose of cyclophosphamide, three groups of
mice (n  7/group) were intravenously inoculated with 1  106 cells of C.
albicans, 1  106 cells of C. parapsilosis, or 1  106 cells of C. tropicalis. A pool
of serum was collected daily for each group for up to 7 days or until the group
died. Animal experiments were approved by the Institutional Animal Care and
Use Committee of the Federal University of Sa˜o Paulo.
Human clinical samples. A total of 20 candidemic patients, diagnosed by a
positive blood culture processed by the Bactec 9240 system, were sequentially
enrolled in this study. Volunteers were selected among patients who signed the
informed consent form and were admitted to the Hospital Sa˜o Paulo, Sa˜o Paulo,
Brazil, between February 2006 and July 2007. Serum samples for antigen detec-
tion were obtained at the time of diagnosis of candidemia and after different
intervals. Stocked serum samples collected from candidemia patients before the
onset of fungemia were also evaluated when available. A pool of serum samples
from healthy volunteers (n  20, blood donors) were included as negative
controls. To verify cross-reactions, sera from patients with active histoplasmosis
(n  3), active paracoccidioidomycosis (n  3), active Jorge Lobo’s disease (n 
3), and active aspergillosis (n  3) were also tested.
RESULTS
Composition of the immunodominant antigen. After SDS-
PAGE of the exoantigens from C. albicans, C. parapsilosis, C.
tropicalis, and C. glabrata, a common protein band of 65 kDa
was found among the three species C. albicans, C. tropicalis,
and C. parapsilosis. C. glabrata did not show this molecule (Fig.
2). In the pilot study, the rabbit anti-C. albicans hyperimmune
serum recognized the 65-kDa antigen present in the exoanti-
gens of C. albicans, C. tropicalis, and C. parapsilosis by immu-
noblotting.
Specificity of the MAb against the 65-kDa protein. After
detecting the presence of the 65-kDa antigen in C. albicans, C.
tropicalis, and C. parapsilosis exoantigens and its detection in
the sera of experimental models and candidiasis human sera
using rabbit polyclonal antibodies (data not shown), MAbs
FIG. 1. Scheme 1. (A) Serum samples were mixed with an equal volume of 0.1 M EDTA and boiled at 100°C to separate antigen/antibody
complexes. (B) The plate was blocked, and samples from panel A were transferred to the inhibition plate and mixed with MAb anti-65-kDa protein.
The MAb was linked to free 65-kDa protein in serum. (C) The MAb/65-kDa protein complex from panel B was transferred to a plate previously
sensitized with the 65-kDa protein (reaction plate). The free MAb was linked to the 65-kDa protein on the plate, and an IgG-peroxidase conjugate
anti-mouse IgG was added. The reaction was developed using chemiluminescent solution, and the degree of inhibition of MAb binding was shown
to be reciprocal to the concentration of circulating antigen in the sample.
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were produced to detect the 65-kDa protein. A panel of dif-
ferent hybridoma lines reactive to C. albicans 65-kDa antigen
was obtained. MAbs belonged to the IgG1 subclass and rec-
ognized an antigenic determinant of C. albicans with a relative
mass of 65 kDa by Western blotting (Fig. 3). This MAb also
recognized the 65-kDa molecule present in C. tropicalis and C.
parapsilosis. This MAb showed no reactivity with exoantigens
of H. capsulatum, S. schenckii, T. rubrum, A. fumigatus, and C.
glabrata and was selected to develop the inh-ELISA test. This
MAb was designated “IgG1-2.”
Dynamics of 65-kDa antigenemia in a murine model of in-
vasive candidiasis by MAb inh-ELISA. The inh-ELISA was
first tested in a murine model of invasive candidiasis before
validation in the human system. Three groups of mice were
infected with C. albicans, C. tropicalis, and C. parapsilosis, re-
spectively. Animals were not challenged with C. glabrata be-
cause the 65-kDa protein was not detected in this species. All
animals presented the 65-kDa protein in serum samples col-
lected daily for up to 7 days. In all three groups, the final serum
sample collection occurred when the infected mice were dead.
In the murine model infected with C. albicans, the 65-kDa
molecule was detected in the range of 0.019 to 2.6 g/ml; in the
C. tropicalis model, the molecule was detected in the range of
0.012 to 3.25 g/ml; and in the C. parapsilosis model, the
molecule was detected in the range of 0.019 to 1.68 g/ml.
Figure 4 shows typical curves obtained from the groups of
animals infected with different Candida species. Antigen con-
centrations higher than 0.23 g/ml (maximum concentration
obtained with 10 normal mouse sera) were considered positive.
Dynamics of 65-kDa antigenemia in patients with invasive
candidiasis. Figure 5 illustrates the standard inhibition curve
FIG. 2. SDS-PAGE showing the presence of the 65-kDa protein in
exoantigens from C. tropicalis (lane 1), C. parapsilosis (lane 2), and C.
albicans (lane 3) and its absence in C. glabrata (lane 4). P, molecular
mass standard.
FIG. 3. Reactivity of the MAb specific for the 65-kDa protein of C.
albicans. The MAb recognized 65-kDa proteins of C. albicans (lane 9),
C. parapsilosis (lane 8), and C. tropicalis (lane 7). Lanes: 1, H. capsu-
latum; 2, A. fumigatus; 3, S. schenckii; 4, P. brasiliensis; 5, T. rubrum; 6,
C. glabrata; P, molecular mass standard.
FIG. 4. Detection of circulating antigens in murine candidemia
models infected with C. tropicalis (A), C. parapsilosis(B), and C. albi-
cans(C) using a MAb. The concentration of circulating antigens in
normal mouse serum was 0.23 g/ml (maximum concentration ob-
tained with 10 normal mouse sera). Dots represent a pooled medium
made up of seven sera.
FIG. 5. Standard inhibition curve of MAb against the 65-kDa pro-
tein of C. albicans constructed with known quantities of purified 65-
kDa protein.
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obtained with known quantities of C. albicans 65-kDa protein.
This curve was used to determine the concentration of 65-kDa
antigen in each sample tested. Antigenemia was present in 20
candidemia patients, from 10 to 87 years of age (median, 47.1
years): 45% were male, and all had been exposed to multiple
risk factors before developing candidemia. All patients were
treated with antifungal drugs 1 to 4 days after the incidence of
candidemia. A total of 16 of the 20 candidemic patients exhib-
ited the 65-kDa protein in concentrations ranging from 0.072
g/ml to 5 g/ml of antigen per ml of serum. Four patients (no.
4, 7, 9, and 10) that had sera collected before the onset of
candidemia presented the 65-kDa protein. Sequential sera pre-
sented three different patterns of antigenemia due to the 65-
kDa molecule: (i) total clearance of antigenemia (Fig. 6A), (ii)
initial clearance and relapse of antigenemia (Fig. 6B), and (iii)
partial clearance of antigenemia (Fig. 6C). An antigen concen-
tration higher than 0.02 g/ml (normal human serum) was
considered positive. Table 1 summarizes the 65-kDa antigen
FIG. 6. Dynamics of 65-kDa antigenemia in patients with invasive candidiasis by MAb inh-ELISA. (A) Total clearance of antigenemia;
(B) initial clearance and relapse of antigenemia; (C) partial clearance of antigenemia. The value 0.02 represents NHS. Crosses indicate death;
smiling faces indicate the patient survived, and a dotted line represents the beginning of treatment.
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concentrations in each patient serum and the species of Can-
dida isolated from blood cultures with the Bactec 9240 system.
DISCUSSION
During pilot studies analyzing exoantigens from the more
prevalent Candida species, isolated from Brazilian patients
with candidemia, we found an intense 65-kDa molecule com-
mon to C. albicans, C. tropicalis, and C. parapsilosis. We hy-
pothesized the presence of this molecule could be used as a
marker of invasive candidiasis. The 65-kDa molecule from C.
albicans was used to produce a hyperimmune serum (in rab-
bits) that was able to recognize this antigen in C. albicans, C.
tropicalis, and C. parapsilosis blot tests. To verify the efficiency
of detection of the 65-kDa antigen in the inh-ELISA system,
the system was tested in a murine experimental model of dis-
seminated candidiasis before its application in a human sys-
tem. The results showed detection of this antigen was possible
in murine candidiasis evoked by the three species of Candida.
To increase the sensitivity of the inh-ELISA test, MAb
against 65-kDa C. albicans was produced and tested in C.
albicans, C. tropicalis, and C. parapsilosis murine models of
disseminated candidiasis infection. During the experiments,
the 65-kDa antigen was detected in concentrations ranging
from 0.012 to 3.25 g/ml of serum and the inh-ELISA was
sensitive enough to detect 100% of the sera tested. The dy-
namics of 65-kDa antigenemia was different in each group; but
in each group, “clearance” of the 65-kDa antigen was observed
in some serum samples collected after infection and the clear-
ance was not dependent on antifungal treatment. The drop in
the level of 65-kDa antigen in mice infected with C. tropicalis
does not necessarily indicate the mice were cleared, because on
the last day sample sera were collected, the group of mice was
dead. The levels in control sera from uninfected animals were
always considered low.
Once the efficiency of antigen detection was established in
murine models with anti-65-kDa MAb, sera from invasive can-
didiasis patients from the ICU were collected for antigen de-
tection. These serum samples were collected at the moment
when the Bactec 9240 blood culture system indicated the pres-
ence of yeasts and also during subsequent days. When possible,
samples were collected before the onset of candidemia.
A total of 20 patients suspected of candidemia were studied,
and 16 (80%) patients were positive for the presence of the
65-kDa antigen, in concentrations ranging from 0.07 to 5.0
g/ml. Three dynamics of 65-kDa antigenemia were observed
among these patients. Four patients experienced a total clear-
ance of 65-kDa antigenemia after treatment with antifungal
drugs: the concentration of 65-kDa antigen in the last sample
tested was less than 0.11 g/ml. Five patients experienced an
initial clearance after treatment with antifungal drugs (with the
exception of patient 1) and a relapse of antigenemia (patient 7
presented an initial clearance, a relapse of antigenemia, total
clearance of antigenemia, and survival after treatment). Seven
patients experienced a partial clearance of antigenemia in
which the concentration of 65-kDa antigen in the last sample
analyzed was greater than 0.25 g/ml. Patients with persistent
65-kDa antigenemia after antifungal treatment did not survive,
with the exception of patient 20. During patient follow-up,
some sequential sera showed “clearance” of the antigen which
may be explained by rapid renal clearance or the host’s im-
mune response. Otherwise, the inh-ELISA was able to detect
the 65-kDa protein in serum samples collected before the
onset of candidemia, indicating its possible use for early diag-
nosis of disseminate candidiasis. Although five species of Can-
dida—C. albicans, C. parapsilosis, C. tropicalis, C. kefyr, and C.
glabrata—were isolated from the blood of these patients, the
65-kDa antigen was detected only in sera from those patients
infected with C. albicans, C. parapsilosis, or C. tropicalis.
It is extremely complex to evaluate the cause of mortality in
patients with candidemia. Considering all underlying condi-
tions present at the moment a patient develops candidemia, it
is possible a significant proportion of patients will have mor-
tality related to candidemia but not attributable to it. Conse-
quently, it is hard to establish a direct connection between
antigen levels and risk of mortality. Data obtained from animal
models suggest that transient clearance of antigen from blood
may occur in animals that will die of systemic infection. In
humans, no positive results were found among the sera from
healthy people.
Available data suggest the inh-ELISA has good sensitivity
and specificity for the diagnosis of candidemia. However, more
data are needed to clarify whether this test may or may not be
used for monitoring clearance of Candida infections from
blood or tissues. Based on our preliminary data, negative inh-
ELISA results were not correlated with survival. In addition,
we observed transient clearance of antigenemia may occur with
further increase of antigen after an interval. Taken together,
this suggests the level of antigen in serum may not correlate in
time with the burden of infection.
Hypothetically, the clearance can be explained either by the
immune response of the host, where phagocytes ingest the
molecule of 65-kDa antigen, decreasing the levels in the serum
of patients at the moment of sample collection, or by filtration
of blood in the kidneys, where the molecule could also be
TABLE 1. Antigen detection by inh-ELISA in sera from patients
with candidemia at the moment of diagnosis
Patient Concn (g/ml) of65-kDa proteina
Species isolated from
blood culture
1 2.24 C. tropicalis
2 ND C. kefyr
3 ND C. glabrata
4 ND C. albicans
5 0.81 C. albicans
6 ND C. glabrata
7 2.56 C. parapsilosis
8 ND C. albicans
9 1.87 C. albicans
10 1.83 C. tropicalis
11 ND C. albicans
12 ND C. albicans
13 1.25 C. albicans
14 5 C. albicans
15 1.3 C. tropicalis
16 1.5 C. albicans
17 1.28 C. tropicalis
18 1.3 C. tropicalis
19 1.75 C. albicans
20 1.98 C. parapsilosis
a Shown is the concentration of 65-kDa protein in sera from patients at the
moment of diagnosis (Bactec positive). ND, not detected.
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eliminated. However, in this study it was not possible to collect
urine from our patients because they were in the ICU with
renal failure. In the future, we will do this analysis.
In this study, some patients presented with the 65-kDa an-
tigen in sera collected before the onset of candidemia (diag-
nosed by the Bactec system). Therefore, in patients suspected
of disseminated candidiasis, we suggest serum samples be col-
lected as early as possible in an attempt to detect this marker
antigen before candidemia is diagnosed by the Bactec system.
Early diagnosis of candidemia would allow for appropriate
antifungal treatment and prevention of Candida dissemination,
reducing the rate of mortality among these patients. Blood
cultures are still considered the “gold standard” for the diag-
nosis of candidemia, as no single molecular method has been
proved superior. This may be confirmed by a recent review of
the criteria for diagnosis of invasive fungal infections published
by NIH (2).
In conclusion, we propose the use of this inh-ELISA system,
using a species-specific MAb, as an additional test for detec-
tion of circulating antigen in patients with candidemia. The use
of the 65-kDa antigen detection system described here will
provide a rapid and specific means of diagnosis. Moreover, this
test has the potential to follow the course of antimycotic ther-
apy by monitoring the reduction in fungal load, as evidenced by
sequential reduction in antigen detection. This will be ad-
dressed in future studies.
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